Clinical trials: Stage II-IV Diffuse Large B Cell Lymphoma
Lymphoma
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: Studying samples of blood in the laboratory from patients who have undergone a donor bone marrow transplant may help doctors learn more about changes that occur in DNA and identify biomarkers related to…
- Trial name
- NCT00898612
- Where
- United States
- Sponsor
- Mayo Clinic
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005804
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Diffuse Large B-cell Lymphoma
Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma
The purpose of this study is to determine whether the treatment of Yt90 Zevalin in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)are effective as first line treatment in patients with bulky…
- Trial name
- NCT00386321
- Testing
- Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)
- Where
- Thailand
- Volunteers
- 10 people
- Sponsor
- Chulalongkorn University
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant.
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
- Trial name
- NCT00569309
- Testing
- Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lymphoma
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00005959
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 27 sites in United States
- Sponsor
- Amgen
Lymphoma
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00070083
- Testing
- oblimersen sodium, rituximab, cyclophosphamide
- Where
- 4 sites in United States, Canada
- Sponsor
- British Columbia Cancer Agency
Leukemia, Lymphoma
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006042
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Diffuse Large B-cell Lymphoma
The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP
The purpose of this study is to determine the effective of Yt90-Zevalin therapy in patients with diffuse large B-cell lymphoma that have achieved at least an unconfirmed partial remission after 6 cycles of CHOP therapy.
- Trial name
- NCT00440583
- Testing
- chemotherapy followed by Zevalin
- Where
- Thailand
- Volunteers
- 15 people
- Sponsor
- Mahidol University
Leukemia, Lymphoma
Immunotoxin in Treating Patients With Leukemia or Lymphoma
RATIONALE: Immunotoxins can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00002765
- Testing
- LMB-2 immunotoxin
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and vincristine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00726700
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Volunteers
- 109 people
- Sponsor
- Universität des Saarlandes
Lymphoma
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop cancer cells, either by killing the cells or by stopping them from…
- Trial name
- NCT01359592
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 240 sites in United States
- Volunteers
- 159 people
- Sponsor
- SWOG Cancer Research Network
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002471
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 4 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, vincristine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00690560
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Antoine Lacassagne
Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00389818
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- 14 sites in United States
- Volunteers
- 43 people
- Sponsor
- AIDS Malignancy Consortium
Leukemia, Lymphoma
Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Adjusting the dose of drugs used in chemotherapy such as cyclophosphamide may decrease side effects while stopping cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00062140
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphoma
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00278408
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 152 sites in Denmark, Germany and 2 more
- Volunteers
- 700 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
RATIONALE: Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells.
- Trial name
- NCT00003163
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Medical College of Wisconsin
Graft Versus Host Disease, Leukemia
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
RATIONALE: A donor peripheral stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00725062
- Testing
- CD4+CD25+ regulatory T cells, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Masonic Cancer Center, University of Minnesota